Introduction
Introduction
Faced with the threat of multimillion-dollar lawsuits, stringent regulatory requirements and opposition from anti-abortion groups, many U.S. drug firms have stopped developing new contraceptives. Non-profits and smaller firms are trying to fill the void, but they don't have the financial resources to sustain the level of research necessary to produce new products and drugs. As a result, ...